Table 2.
Serological response following three-dose vaccination in patients
| Anti-Spike antibody level BAU/mL, median (IQR) | |
| Patients overall third dose | 5720 (2138–8732) |
| Diagnoses | |
| Rheumatoid arthritis | 5993 (2407–9855) |
| Spondyloarthritis | 4549 (1897–8358) |
| Psoriatic arthritis | 6891 (3065–9405) |
| Ulcerative colitis | 5513 (2016.5–8130) |
| Crohn’s disease | 4978 (1877–7929) |
| Medication | |
| Tumour necrosis factor inhibitor, monotherapy* | 5174 (2000–7856) |
| Tumour necrosis factor inhibitor combination therapy† | 4252 (1475–8322) |
| Methotrexate | 7464 (4239–10685) |
| Vedolizumab | 7758 (5033–9606) |
| Janus kinases inhibitor | 2527 (895–6439) |
| Tocilizumab, ustekinumab and secukinumab | 7083 (4803–9569) |
| Abatacept | 4547 (1551–6613) |
| Other‡ | 9625 (7647–10190) |
| Vaccines | |
| BNT162b2 | 4628 (1694–7719) |
| mRNA-1273 | 6610 (3764–10084) |
| Combination of vaccines§ | 7154 (2810–9797) |
| Other factors | |
| Age groups | |
| Age <30 years | 7158 (3337–9465) |
| Age 30–65 years | 5784 (2270–8701) |
| Age >65 years | 4758 (1626–8331) |
*Tumour necrosis factor inhibitors: infliximab, etanercept, adalimumab, golimumab, certolizumab pegol.
†Combination therapy: tumour necrosis factor inhibitor in combination with either methotrexate, sulfasalazine, leflunomide or azathioprine.
‡Drugs with less than 10 patients included: sulfasalazine, leflunomide, azathioprine, risankizumab, prednisolone monotherapy.
§Combination of the following vaccines: ChAdOx1, BNT162b2, mRNA-1273
BAU, binding antibody unit; IQR, Inter quartile range.